Regeneron Pharmaceuticals (NASDAQ:REGN) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $5.24 by ($0.79), MarketWatch Earnings reports. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.76 billion. During the same quarter last year, the business earned $4.67 earnings per share. The business’s revenue for the quarter was up 13.3% compared to the same quarter last year.
NASDAQ REGN traded down $16.61 during trading hours on Tuesday, hitting $327.62. The company had a trading volume of 17,429 shares, compared to its average volume of 876,195. Regeneron Pharmaceuticals has a fifty-two week low of $281.89 and a fifty-two week high of $442.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.47 and a quick ratio of 3.67. The firm has a market capitalization of $36.81 billion, a PE ratio of 16.58, a P/E/G ratio of 1.31 and a beta of 1.08.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a document filed with the SEC, which is available through this link. 12.42% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Smithfield Trust Co. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $27,000. Whittier Trust Co. increased its holdings in shares of Regeneron Pharmaceuticals by 195.7% during the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 45 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $29,000. Rehmann Capital Advisory Group increased its holdings in shares of Regeneron Pharmaceuticals by 1,700.0% during the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 68 shares during the period. Finally, AdvisorNet Financial Inc increased its holdings in shares of Regeneron Pharmaceuticals by 208.0% during the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 52 shares during the period. 66.38% of the stock is currently owned by institutional investors.
Several equities analysts recently issued reports on REGN shares. TheStreet upgraded Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Cowen restated a “hold” rating and set a $385.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, January 7th. BidaskClub cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $441.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 6th. Finally, Oppenheimer increased their target price on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the stock an “outperform” rating in a research report on Thursday, February 7th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $413.56.
COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals (REGN) Issues Quarterly Earnings Results, Misses Estimates By $0.79 EPS” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thelincolnianonline.com/2019/05/07/regeneron-pharmaceuticals-regn-issues-quarterly-earnings-results-misses-estimates-by-0-79-eps.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: Calculating net profit and net profit margin ratio
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.